Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 153 | — | — | Sep 6, 2021 | Jul 1, 2025 | Jun 21, 2024 | 42 | United States, Belgium +4 |
| Arm | Type | Description |
|---|---|---|
| Part 1A - EOS-448 + pembrolizumab | EXPERIMENTAL | Participants will receive EOS-448 and pembrolizumab at every cycle |
| Part 1B - EOS-448 + inupadenant | EXPERIMENTAL | Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis |
| Part 1C - EOS-448 + inupadenant | EXPERIMENTAL | Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis |
| Part 1D - EOS-448 + dostarlimab | EXPERIMENTAL | Participants will receive EOS-448 and dostarlimab at every cycle |
| Part 1E - inupadenant HCl + dostarlimab | EXPERIMENTAL | Participants will receive dostarlimab at every cycle and inupadenant on an ongoing basis |
| Part 1F - EOS-448 + dostarlimab + inupadenant HC | EXPERIMENTAL | Participants will receive EOS-448 and dostarlimab at every cycle and inupadenant on an ongoing basis |
| Part 1G - EOS-448 + dostarlimab + chemotherapies | EXPERIMENTAL | Participants with 1L mNSCLC will receive EOS-448 and dostarlimab and chemotherapies at every cycle |
| Part 2C - EOS-448 + dostarlimab | EXPERIMENTAL | Participants with 1L mHNSCC CPS ≥ 20 will receive EOS-448 and dostarlimab at every cycle |
| Part 2D - EOS-448 + dostarlimab | EXPERIMENTAL | Participants with 1L mHNSCC 1 \< CPS \< 20 will receive EOS-448 and dostarlimab at every cycle |
| Name | Type | Description |
|---|---|---|
| EOS-448 | DRUG | Anti-TIGIT monoclonal antibody |
| pembrolizumab | DRUG | Anti-PD-1 monoclonal antibody |
| inupadenant | DRUG | A2A receptor antagonist |
| Dostarlimab | DRUG | Anti-PD-1 monoclonal antibody |
| SOC chemotherapies | DRUG | SOC chemotherapies in 1L mNSCLC |
Inclusion Criteria: * Provide a signed written informed consent for the trial * Have measurable disease, per RECIST v1.1 * Have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 or 1. * Have adequate organ functions * Part 1A/1B/1C/1D/1E/1F: Have histologically or cytologic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |